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Introduction
Diseases caused by trypanosomatids constitute a substantial
health and socioeconomic problem in several countries, mainly in
the Americas, sub-Saharan Africa and tropical and subtropical belt
regions. In particular, Chagas’ disease, (caused by Trypanosoma
cruzi) affects 8 to 10 million people in the Americas, with an addi-
tional 40 million people at risk (www.who.int/tdr). T. cruzi has a
complex life cycle involving a reduviid insect vector and a mam-
malian host (Fig. 1). Insect vectors become infected when they
bite an infected mammal that has trypomastigote forms of the par-
asite circulating in its bloodstream. Trypomastigotes, infective
non-dividing forms, are ingested with the blood; in the insect’s
digestive tube, they differentiate into dividing and non-infective
epimastigote forms. In the terminal portion of the digestive tube,
epimastigotes differentiate into metacyclic trypomastigotes, which
are eliminated in faeces and deposited on mammals’ skin while the
triatomine bug bites and feeds. Trypomastigotes enter the body
and invade host cells; they differentiate into dividing amastigote
forms and after proliferating, differentiate into trypomastigotes,
passing through a transient epimastigote-like stage. Finally, the
trypomastigotes lyse host cells and are released into the extracel-
lular medium, where they can invade other cells or the blood-
stream, becoming capable of invading other tissues or a non-
infected reduviid insect, thus completing the cycle [1].
Chagas’ disease
Chagas’ disease presents mainly as two clinical phases in human
beings: acute and chronic. The acute phase happens shortly after
infection, beginning when the parasite enters the mammalian host.
It is either largely asymptomatic or accompanied by non-specific
symptoms such as fever and headache. It is characterized by an
absence of antibodies and, in most patients, a conspicuous para-
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sitemia starting 1 or 2 weeks after parasite entry. In some cases,
specific symptoms such as lymphadenopathy and splenomegaly,
myalgia, malaise, muscle pains, sweating, hepatosplenomegaly or
heart failure from myocarditis or pericardial effusion may be pres-
ent. Less often, meningoencephalitis can occur, which can lead to
death [2]. The chronic phase, in principle, can last for the patient’s
entire lifetime [3], beginning with the decline of parasitemia. It is
defined by an initial absence of symptoms. The main chronic forms
are indeterminate, cardiac (chronic chagasic cardiomyopathy, or
CCC) and digestive. At lower frequencies, the chronic phase can
consist of alterations in the peripheral nervous system. The inde-
terminate form is characterized by the absence of evident tissue
damage and organ dysfunction and can last from several months
to the patient’s entire life, which is the case for approximately 70%
of chronically infected people. The remaining 30% develop one of
the symptomatic forms, most frequently CCC. This form presents
different degrees of severity, ranging from mild symptoms to heart
failure (caused by inflammation and fibrosis), frequently followed
by sudden death. The main clinical manifestation of CCC is car-
diomegaly caused by inflammatory infiltrations, arrhythmias and
thromboembolism. The lesions can affect the right ventricle, caus-
ing oedema and congestive hepatomegaly [3]. The digestive form
consists of two syndromes: megaesophagus, leading to dysphagia
and regurgitation, and megacolon, leading to severe constipation
and faecal retention [4]. In immunocompromised patients, severe
compromise of the central nervous system has been also reported
[5]. In conclusion, although the majority of T. cruzi infected individ-
uals remain asymptomatic for their entire lives, a percentage of the
infected population will develop serious symptoms.
Chemotherapy
Despite the fact that Chagas’ disease was first described a century
ago, only two therapeutic compounds presently in use have been
shown to be useful against human infections by T. cruzi: benznida-
zole (BZL) and nifurtimox (NF) (Fig. 2). BZL, a nitroimidazole, was
launched in the 1970s; in most Latin American countries, it is the
only drug used to treat Chagas’ disease. This treatment is effective
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Fig. 1 Schematic representation of 
the Trypanosoma cruzi life cycle.
Replicative, non-infective epimastigote
forms (A), predominantly present in the
insect vector, give rise to non-replica-
tive, infective metacyclic trypomastig-
otes (B). Metacyclic forms must invade
the host cells and differentiate into
replicative amastigote forms (C) to
establish the infection. These forms give
rise to a transient stage called intracellu-
lar epimastigotes (D), which subse-
quently differentiate into trypomastig-
otes (E). Trypomastigotes can dissemi-
nate in the mammalian host through the
bloodstream. The insect vector eventu-
ally can take these forms during its
bloodmeal. The cycle ends when the
ingested trypomastigotes differentiate
again into epimastigotes (A), which col-
onize the digestive tube of a new insect.
Fig. 2 Molecular formula of BZL and NF.
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for acute phase infections, congenital infections, reactivated infec-
tions and early chronic disease. However, its efficacy during the
chronic phase is controversial [6]. The key mode of action of BZL
seems to be based on interference with the synthesis of macromol-
ecules via covalent binding between nitroreduction intermediates
and various cellular components such as DNA, lipids and proteins
of the parasite. BZL has also been shown to improve phagocytosis,
increase trypanosomal death through interferon (IFN)- production
and inhibit T. cruzi NADH-fumarate reductase [7]. The mechanism
of action of NF involves the generation of nitroanion radicals by
nitroreductases that, in the presence of oxygen, produce reactive
intermediates to which T. cruzi is susceptible. Considerable efforts
are being made to identify promising targets for new drugs. A
detailed discussion of new drugs with chemotherapeutic perspec-
tives is outside the scope of this review. However, some T. cruzi
specific pathways contain proteins/enzymes that are being vali-
dated as targets; several drugs that interfere with these targets are
particularly promising [6]. The cysteine proteinases of T. cruzi,
which participate in cellular processes such as energy metabolism,
differentiation, host cell invasion and evasion of the immune sys-
tem, have been validated as drug targets [8]. In particular, the use
of synthetic inhibitors such as vinyl sulfone-derivatized dipeptides
has shown promising results in vivo [9, 10]. In addition, sterol and
polyisoprenoid biosynthesis pathways provide promising targets,
because ergosterol (rather than cholesterol) is the main sterol in 
T. cruzi membranes [11]. Specific inhibitors such as azole deriva-
tives [12] and bisphosphonates [13, 14] have been tested in vitro
or in vivo. Inhibitors of T. cruzi specific enzymes such as trypan-
othione reductase [15], arginine kinase [16] and proline racemase
[17] have shown promising trypanocidal activities. It was recently
shown that proline transporters could also be relevant targets
[18]. Allopurinol, an inhibitor of purine (hypoxanthine/guanine)-
phosphoribosyl-transferase, has been proposed for treating 
T. cruzi reactivation infection in patients after heart transplantation
[19]. Inhibitors of topoisomerases I and II [20, 21], which are
involved in nuclear and kinetoplastid DNA replication, were
 efficient in blocking T. cruzi growth. Parasite DNA has also been
proposed as a target for intercalators and binders with trypanoci-
dal activity [22–24].
Immune response in experimental 
T. cruzi infection
T. cruzi’s success in maintaining its life cycle is dependent on its
capacity to cause chronic infection in the host, thus favouring
encounters with insect vectors. To maintain latent infection, a bal-
ance between parasite and host immune response is necessary.
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Fig. 3 Schematic representa-
tion of the protective immune
response during T. cruzi acute
infection. Antigen-presenting
cells are among the first cells
that become infected by the try-
pomastigotes when they enter
the mammalian host. Normally,
the cells react by up-regulating
IL-6, IL-1, TNF-, IL-12 and
nitric oxide in an attempt to
control the infection. NK cells
are among the first line of
responders and usually pro-
duce high levels of IFN- when
stimulated by IL-12. The stimu-
lus of the Th1 profile and the
CD8 T cells contributes to
eliminate the intracellular
amastigotes in infected tissues.
On the other hand, the parasite
antigens stimulate a Th2 profile
which contributes to the pro-
duction of specific antibodies.
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Host resistance to Chagas’ disease depends on both innate and
adaptive immunity (Fig. 3) [25–27]. Different cell types and mole-
cules are involved in the response against experimental T. cruzi
infection, as summarized in Table 1. Generally, the absence of
some component(s) of the immune response leads to greater sus-
ceptibility to T. cruzi infection, resulting in higher parasitemia and
mortality rates.
With respect to the innate immune mechanisms triggered by
the parasite, it has been found that some pathogen-associated
molecular patterns derived from T. cruzi are recognized by specific
receptors known as pattern recognition receptors (PRRs) [28].
The toll-like receptor (TLR) family is the best characterized class
of mammalian PRRs [29]. Mice that are unable to signal through
most TLRs (MyD88 knockout [KO] or MyD88/TRIF double KO) are
highly susceptible to T. cruzi infection, suggesting that resistance
to acute T. cruzi infection is dependent on TLR signalling [30, 31].
T. cruzi derived glycosylphosphatidylinositol (GPI) anchors and
glycoinositolphospholipids (GIPLs) were shown to have
immunoregulatory properties and were present in significant
quantities on the parasitic surface. GPIs are recognized by the
transmembrane receptor TLR-2, which is associated with CD14.
Interestingly, T. cruzi infected TLR-2 KO mice are able to produce
pro-inflammatory cytokines, yet parasitemia and mortality rates
are not different from wild-type animals [30]. It has also been
shown that GIPLs are recognized via TLR-4, and TLR-4 KO mice
are more susceptible to T. cruzi infection than wild-type mice [28].
However, the role of these molecules in natural infection has not
been assessed. T. cruzi DNA binds TLR-9 and has been reported
to stimulate macrophages and DCs to express interleukin (IL)-12,
tumour necrosis factor (TNF)- and nitric oxide [32]. In fact, TLR-
9 KO mice are highly susceptible to T. cruzi infection, and some
results suggest that TLR-2 and TLR-9 cooperate to control T. cruzi
© 2010 The Authors
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KO Phenotype/absence of: Effect on parasitemia Effect on mortality Reference
Immunoglobulin 
heavy chain
B lymphocytes
Increase 
(end of acute phase)
Increase [35]
 Chain Mature B lymphocytes Increase Unaltered [75]
CD4 CD4 T lymphocytes Increase Increase [26]
CD8 CD8 T lymphocytes Increase Increase [26]
MHC class I and II CD4 and CD8, T lymphocytes Increase Increase [27]
2 Microglobulin CD8 T lymphocytes and NK cells Increase Increase [27]
 chain of the 
T lymphocyte receptor
 T lymphocytes Unaltered Decrease [48]
IFN- IFN- production Increase Increase [57]
IFN- receptor Activation by IFN Increase Increase [55]
NOS2 Nitric oxide production Increase Increase [55,58]
IL-10 IL-10 production Decrease Increase [67]
IL-12 IL-12 production Increase Increase [57, 64]
TNF- receptor
Activation by TNF-, reduction 
of Ig production
Increase Increase [65]
Perforin Perforin Unaltered Unaltered [35]
Granzime B Granzime B Unaltered Unaltered [35]
Stat4 CD4 Th1 response Increase Increase [37]
Stat6 CD4 Th2 response Unaltered Unaltered [37]
MyD88 Absence of signalling through some TLRs Increase Increase [30]
TLR-2 Absence of signalling through TLR 2 Unaltered Unaltered [30]
TLR-4 Absence of signalling through TLR 4 Increase Increase [28]
TLR-9 Absence of signalling through TLR 9 Increase Increase [33]
CD1d NK T cells Decrease Not assessed [52]
Table 1 Effect of the absence of different molecules of the immune system in the experimental acute infection by Trypanosoma cruzi
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replication during acute infection [33]. In summary, these data
suggest an important role for TLR signalling pathways in the
innate immune response to T. cruzi infection.
To unravel the role of cellular immune responses, initial exper-
iments have been performed in which T cells were adoptively
transferred from chronically infected to naı¨ve mice. Significant
protection was observed after experimental challenge with T. cruzi
[34]. Both CD4 and CD8 () T-cell subsets appear to be
important for the generation of protective immunity against acute
experimental T. cruzi infection [26, 27, 35, 36].
Tarleton and collaborators showed that Th1 CD4 T cells are
important for controlling T. cruzi infection, while Th2 cells con-
tribute to parasite persistence and increased disease severity [37].
Attempts to obtain protective vaccines against defined T. cruzi
antigens have also provided valuable information about the role of
Th1-type responses during infection. For example, cruzipain,
when used as an antigen in immunization protocols, significantly
improved immune responses in animals challenged with a lethal
dose of the parasite [38] and precluded tissue damage [39].
CD8 T cells also seem to play a role in T. cruzi infection by
killing infected cells through the production of perforin and
granzyme B or through the Fas/Fas ligand pathway. Acute infection
with the Brazil strain of T. cruzi did not enhance the susceptibility
of either perforin or granzyme B KO mice [35]. By contrast, previ-
ously reported data have shown that mice lacking perforin and
granzymes A and B are more susceptible to infection with the
Tulahuen strain [40]. Increased susceptibility to infection with the
Tulahuen strain was also observed in mice deficient in the Fas/Fas
ligand pathway [40]. T. cruzi antigens that are CD8 T-cell targets
have also been studied using chronically infected mice. These
studies showed that epitopes from the trans-sialidase family of
proteins are immunodominant, and the CD8 T-cell response is
focused mainly on very specific epitopes [41, 42]. When surface
markers of some of these cell populations were analysed, it was
found that they were central memory T cells that are maintained
even during persistent T. cruzi infection [43]. Immunization proto-
cols using plasmid DNA coding for the proteins trans-sialidase
and amastigote surface protein-2 have also shown that both cellu-
lar and humuoral immune responses were induced, and the pres-
ence of CD4 Th1 and CD8 specific T cells was shown.
Furthermore, parasitemia and/or mortality reduction was seen in
mice infected with the Y [44–46] or Brazil strains of T. cruzi [47].
The effective participation of  T cells in the immune
response against T. cruzi is still controversial. These cells were
found to be deleterious for the host in a study in which -KO
mice had lower mortality rates and fewer areas with skeletal and
cardiac inflammatory lesions compared to wild-type mice [48]. On
the other hand, an increase in susceptibility was observed in 
T-cell depleted animals after experimental infection associated
with a reduction in IFN- production [49].
The immune response against T. cruzi is also influenced by NK,
NK T and regulatory T cells (T reg). The relevance of NK cells in
acute T. cruzi infection was demonstrated when normal, NK-
depleted mice showed a significant increase in parasitemia and
mortality rates [50, 51]. NK T cells are activated by glycolipids pre-
sented via CD1d molecules and act by limiting parasitemia. These
cells also seem to influence antibody responses during chronic
Chagas’ disease [52]. The role of regulatory T cells (CD4 CD25)
during T. cruzi infection was also shown through depletion.
Controversial results were obtained with mice infected with differ-
ent T. cruzi strains: no effect was seen when Brazil and Tulahuen
strains were used [53], while limited effects were seen with the
Colombian strain [54]. No role was observed for these cells dur-
ing chronic infection of mice with the Colombian strain [54].
The role of IFN- during T. cruzi infection was demonstrated
when IFN- and IFN- receptor KO mice showed higher rates of
parasitemia and mortality [55]. Infected IFN- KO mice showed
increases in cellular infiltrates in the heart and skeletal muscles
and reduced survival [36, 56, 57]. The role of the inducible nitric
oxide synthase (iNOS) was also studied. iNOS KO mice showed
greater parasitemia in the acute phase and rapid mortality com-
pared to control animals [55, 57, 58]. Additionally, nitric oxide
seems to have an effect on the generation of the inflammatory
heart infiltrate seen during T. cruzi infection by modulating
chemokine expression. Cardiomyocytes from iNOS KO mice that
were stimulated with IFN- and TNF produced significantly higher
levels of the chemokines CCL2, CCL4, CCL5 and CXCL2 [59].
Other chemokines and chemokine receptors have also been
analysed during acute or chronic T. cruzi infections. CXCL9,
CXCL10 and CCL5 are expressed in the heart during both phases
of T. cruzi infection [60, 61]. Their presence correlates with the
expression of IFN- and TNF- and the presence of inflammatory
cells. However, their ablation did not modulate the severity of heart
inflammation [61]. During the acute phase, CCR5 seems to be crit-
ical to controlling the migration of CD4 and CD8 T cells to the
heart [62], but it does not seem to play an important role in main-
taining an inflammatory response in the heart during chronic
infection [63].
IL-12 is also extremely important for controlling the infection,
as IL-12 KO mice show higher rates of parasitemia and mortality
compared to controls [57, 64]. The role of TNF- is controversial:
TNF receptor p55 KO mice [25, 65] showed increased parasitemia,
while parasitemia and mortality rates in TNFR1 KO mice did not dif-
fer from wild-type [66]. IL-10 deficiency leads to parasitemia
reduction; however, mortality is accelerated due to a dramatic
increase in acute pathology [67]. IL-4 seems to have different
effects according to the parasite strain. IL-4 KO mice infected with
the Y strain did not differ from wild-type in terms of parasitemia
and mortality [68]. However, when the Colombian strain was used,
IL-4 KO mice showed reduced parasitemia and mortality rates [57].
The importance of antibodies for controlling chronic infection
was demonstrated when sera from chronically infected chagasic
patients or mice were transferred to naı¨ve mice, significantly
reducing parasitemia and prolonging survival after challenge with
T. cruzi [69, 70]. Protective antibodies are also able to agglutinate
trypomastigotes in vitro [70], lyse them in a complement-medi-
ated fashion [71], facilitate phagocytosis/opsonization [72] and
mediate antibody-dependent cellular cytotoxicity [73, 74]. During
acute T. cruzi infection, B cells also play fundamental roles in both
the recruitment of CD4 T cells and CD8 T cells to the spleen
© 2010 The Authors
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and in the generation and maintenance of central memory and
effector T cells. KO mice lacking mature B cells (MT KO) pro-
duced decreased amounts of inflammatory cytokines and fewer
central and memory CD4 and CD8 T cells compared to wild-
type T. cruzi infected mice. An increase in parasitemia was
observed in muMT KO mice, but no difference was seen in terms
of survival [75]. B cells are also able to participate in the cross-
priming of specific CD8 T cells, inducing systemic and mucosal
protective immunity against experimental infection [76]. Taken
together, these results suggest the important participation of both
innate and adaptive immune responses during experimental 
T. cruzi infection.
Immune response in human beings
infected with T. cruzi
During the chronic phase of Chagas’ disease, the majority of indi-
viduals show potent cellular and humuoral immune responses
[77, 78]. The relevance of a strong immune response for parasite
control has been shown by the fact that chemically immunosup-
pressed individuals [79] and AIDS patients can develop sympto-
matic forms of the disease [80]. The mechanisms underlying the
transition from asymptomatic to clinically symptomatic are still
unclear. Several factors may be involved, such as differences in
parasite strain, parasite load, infection time, host genetic back-
ground and immune response. In animal models, different para-
site strains, mouse backgrounds and re-infections can play a role
in the development of heart pathology and/or protection [81–83].
Regarding human infections, a study with patients acutely
infected with T. cruzi has shown that CD4 and CD8 T cells are
present in endomyocardial biopsies where myocarditis was also
detected in 100% of the cases, reinforcing the role of the immune
response in acute pathology [84]. With respect to the chronic
phase, a predominance of activated CD8 T cells was found in
myocardial biopsy fragments from patients with CCC [85, 86]. It
is also of interest that peripheral blood mononuclear cells
(PBMCs) from chronically infected chagasic patients were able to
produce IFN- upon stimulation with recombinant T. cruzi derived
proteins [87, 88]. Furthermore, PBMCs from CCC patients pro-
duced more IFN- and less IL-10 [87, 89]. IL-10 expression in
monocytes from patients with the indeterminate form was higher
than in cardiac patients [89, 90]. By contrast, analysis of IFN--
producing CD8 T cells present in infected patients (with unde-
tectable, mild or more severe forms of clinical disease) showed
that there was a negative correlation between the capacity of their
cells to respond to T. cruzi amastigote antigens and disease sever-
ity [91]. A careful analysis of these cells showed that in respond-
ing individuals (individuals with milder heart disease), there were
early differentiated (CD27CD28) and effector memory
(CD45RACCR7) CD8 T cells. On the other hand, individuals
with more severe forms of the disease presented fully differenti-
ated (CD27CD28) CD8 T cells [77]. The authors suggest that
this profile is compatible with the hypothesis that as the disease
progresses, there is a gradual clonal exhaustion of the CD8 T-cell
population, probably due to continuous antigenic stimulation.
Another study showed that patients with cardiac forms of Chagas
disease display a high frequency of circulating CD4 and CD8 T
cells lacking the CD28 surface molecule [78]. Two cytokines (IL-7
and IL-15) were suggested as being important for the survival of
CD8 T cells in the cardiac infiltrate [92].
On the other hand, there is also evidence that activated T cells
are involved in Chagas disease pathology. Cells from patients with
chronic infections (either symptomatic or asymptomatic) express
both inflammatory and anti-inflammatory cytokines [93, 94], sug-
gesting that there is probably immune regulation during the
chronic phase. However, preferential expression of TNF- and
IFN- (both inflammatory cytokines) was observed in cardiac
lesions [33, 86] and has been associated with progressively
severe cardiac disease [89, 95]. Few reports have focused on the
identification the CD8 T-cell targets in chronic chagasic patients
[41, 91, 96–98], probably due to the fact that these responses are
not very strong. CD8 T-cell responses against T. cruzi peptides
derived from the proteins cruzipain, FL-160, KMP-11 and the
trans-sialidase family were detected in infected individuals [41,
97, 98]. Peptides derived from the trans-sialidase protein family
were able to bind to six of the most common class I HLA super-
types, and the stimulated cells showed a lack of polyfunctional
cytokine responses, producing only IFN- [96].
Evidence has also led to the proposal of an autoimmune
hypothesis for the disease, suggesting that the symptoms pre-
sented by infected individuals are a consequence of the triggered
immune response rather than parasite persistence [99]. However,
autoimmunity is not sufficient to explain the multifocal nature of
myocarditis and the preferential location of fibrosis in certain
regions, such as the apical or posterior left ventricular wall in the
cardiac form of Chagas’ disease [100]. Moreover, as mentioned
above, frequent positive xenodiagnosis during the chronic phase
of the disease and episodes of reactivation in immunocompro-
mised patients has provided evidence that the parasite is present
even under active control of the host immunological system [79].
In fact, recent studies have described a positive correlation
between myocardial parasite persistence and high-grade
myocarditis [101, 102]. These studies reinforce the notion that a
combination of immune response and parasite persistence deter-
mines the development of Chagas’ disease pathology. However,
the specific mechanisms that trigger the symptoms seen during
the chronic phase are still elusive.
Immune response in the treatment 
of chagasic infection
As previously mentioned, the resistance developed during exper-
imental Chagas’ disease depends on innate immune responses as
well as on a prevalent Th1 response at the beginning of infection.
© 2010 The Authors
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In addition, the antibodies produced by a Th2 response can con-
tribute to the control of in vivo parasite replication (schematized
in Fig. 3). Several works have shown that chemotherapy acts by
unbalancing the equilibrium between the host immune response
and the parasite in favour of the host [66, 103]. However, it is
important to stress that the results obtained with both drugs used
for treatment, BZL and NF, differ strongly according to the disease
phase, the time extension and the drug dose, as well as the
patient’s age and geographical origin [104]. In vitro phagocytosis
and intracellular destruction of trypomastigotes by mouse peri-
toneal macrophages collected from animals treated with NF and
BZL are remarkably increased compared to untreated controls
[105]. The effects of in vivo treatment with BZL on parasite-
macrophage interaction have been studied using the Y strain of 
T. cruzi. Drug-resistant and drug-susceptible parasites from 
this strain were used, and it was observed that BZL enhanced
phagocytosis, parasite destruction and cytokine release by
macrophages when a drug-sensitive strain was used.
Splenocytes from these animals produced very high levels of
TNF- and reactive nitrogen intermediates [106]. BZL treatment
was also evaluated in IFN-, IL-12, TNF receptor and iNOS KO
mice. Although BZL treatment was able to cure 100% of wild-type
mice, it was not as effective when various KO mice were used
[107]. The induction of a stable parasite-specific CD8 T-cell
population with the characteristics of central memory was
observed in chronically infected mice treated with BZL. These
cells also expand more rapidly and provide greater protection
after challenge compared to cells from non-treated chronically
infected mice [108]. It was also observed that splenomegaly per-
sisted in spite of amelioration of clinical and parasitological signs
in infected and BZL-treated mice. This was due to a preferential
expansion of effector and memory CD8 T cells but not of
recently activated CD4 and CD8 T cells, suggesting that BZL
directly affects immunoregulation in T. cruzi infected mice [109].
The effect of BZL treatment was also studied in two CCC mouse
models, showing contradictory results. One model showed that
treatment was able to reduce the severity of cardiac autoimmune
disease [82], while in the other, early treatment with BZL did not
alter the intensity of CCC [110].
PBMCs from cured patients treated with BZL during the acute
phase showed stronger proliferative responses and IFN- produc-
tion compared to non-cured patients. IFN- could be acting
 synergistically with chemotherapy to eliminate parasites [111], 
as previously suggested [112]. It was also demonstrated that
most individuals with an indeterminate clinical form show a dom-
inant regulatory cytokine profile, whereas individuals with CCC
display a dominant inflammatory cytokine pattern. Interestingly,
an inversion of the cytokine profile (from an inflammatory to a reg-
ulatory profile or vice versa) was found after in vivo treatment of
indeterminate and cardiac individuals with BZL [113]. Cytokine
expression in T. cruzi infected children treated with BZL shifted
toward a type 1 modulated immune profile, and IFN- was mainly
produced by NK cells and CD8 T lymphocytes [103]. Although a
pro-inflammatory immune response is commonly related to
Chagas’ disease pathogenesis, it is also important for treatment
effectiveness. A longitudinal study performed to evaluate
immunological status following BZL treatment during early inde-
terminate Chagas’ disease demonstrated that BZL treatment
induced substantial T- and B-cell activation [114].
As discussed above, several lines of evidence show that BZL,
in addition to having trypanocidal activity, acts as an immunomod-
ulator. More specifically, the fact that BZL is known to affect mam-
malian host cells raised the hypothesis that it might be affecting
macrophage metabolism. Revelli and collaborators showed that
BZL down-regulates nitric oxide and pro-inflammatory cytokine
synthesis (IL-6, IL-1) by lipopolysaccharide (LPS)-stimulated
RAW 264.7 murine macrophages and leads to an inhibition of
iNOS gene expression [115] through the inhibition of NF-	B acti-
vation [116]. Moreover, in a rat model of acute T. cruzi infection,
systemic treatment with BZL led to a marked reduction of nitric
oxide derived metabolites, suggesting that the beneficial proper-
ties of BZL may depend on both trypanocidal action and
immunomodulating effects [117]. These properties of BZL have
been further demonstrated by its ability to increase survival and
decrease serum levels of IL-6 and TNF- in C57BL/6 mice chal-
lenged systemically with LPS [118]. In an infectious-based situa-
tion of systemic inflammatory response (cecal ligation and punc-
ture, CLP), mice treated with BZL had an increased survival rate
and a significant reduction of TNF- levels and bacteremia 24 hrs
after CLP [119]. Such beneficial properties may broaden the
potential use of BZL in hyperacute cases where inflammatory
responses become harmful.
There are limited data concerning the effects of NF on immune
responses, mainly because treatment with this drug was discon-
tinued in the 1980s. At the experimental level, no gross changes
in cell-mediated immunity were recorded in NF-treated mice
[120]. However, an impaired PPD skin reaction was seen in guinea
pigs when this compound was administered [121]. From a clinical
standpoint, chronically infected human beings who were treated
for two months with NF had a detectable peripheral leukocyte
migration inhibition test to T. cruzi antigens. Migration was lower
in untreated patients, and further treatment improved such
responses [122]. The effect of NF treatment on re-infection has
also been evaluated. Animals that were parasitologically sterilized
by NF treatment and re-infected with a small number of parasites
showed parasitemia and mortality rates similar to control animals
(infected, non-treated). However, when re-infection was per-
formed with a large number of parasites, parasitemia and mortal-
ity were increased compared to controls. Immunological studies
have shown that NF treatment reduces the levels of antibodies
engaged in parasite destruction, reducing either complement-
dependent lysis or antibody-dependent cytotoxicity. No difference
was observed when treated and non-treated mice were compared
in terms of T-cell mediated immunity. Therefore, it seems that NF
treatment leads to a loss of resistance to re-infection with a high
number of parasites [120].
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The need for new therapeutic
 alternatives for Chagas’ disease
During the last 40 years, therapy for Chagas’ disease has been based
solely on two drugs: NF and BZL. The search for new trypanocidal
drugs as well as other strategies to improve immune responses
 during infection (i.e. therapeutic vaccines) are currently under way
[123, 124]. Treatment of the symptomatic complications of Chagas’
disease, mainly related to heart failure, is also effective in improving
quality of life. Heart transplantation [125] and cellular therapy with
stem cells [126] are therapeutic options for patients with advanced
CCC, but both require optimization of the etiological treatment. As
more data become available regarding the relevance of parasite per-
sistence in the development of chronic infection, the search for new
treatments becomes extremely critical. Future challenges for develop-
ing new drugs for Chagas’ disease reside in finding compounds that
show both trypanocidal and immunomodulatory activities. Despite
the vast literature regarding the anti-T. cruzi activity of myriad com-
pounds, only a small fraction of studies explore the characteristics
mentioned above. Furthermore, drugs with modest anti-T. cruzi activ-
ity could be evaluated as co-adjuvant drugs, interacting synergistically
with NF or BZL. This strategy would increase the spectrum of avail-
able combinations and possibly contribute to reducing the dose and
thus avoiding the toxic effects of the drugs currently in use.
Conclusions
In summary, the drugs that are available to treat diseases caused
by trypanosomatids are somewhat effective. However, for the rea-
sons discussed above, new drugs that are able to act alone or in
concert with current treatments as well as with strategies such as
immunotherapy and vaccines are urgently needed. These are rele-
vant goals because they could aid in reducing undesired second-
ary effects, thereby optimizing the quality of life of patients and
diminishing treatment evasion. In this way, funding of all steps
related to the development of new therapies, from validation of
new targets to evaluation of new drugs (from the bench top to
clinical trials), is a necessity.
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